InvestorsHub Logo
Followers 34
Posts 4311
Boards Moderated 0
Alias Born 07/16/2014

Re: lunatick post# 2321

Tuesday, 07/21/2015 7:13:32 PM

Tuesday, July 21, 2015 7:13:32 PM

Post# of 3108
It would make sense

"This study is designed to evaluate CLBS03 in adolescents with type 1 diabetes mellitus (T1DM). We look forward to starting this Phase 2 trial later this year or in early 2016. In the meantime, we are exploring means, including partnering, by which we can accelerate the initiation of the trial and the immunomodulation program in general."

http://www.caladrius.com/2015shareholderletter/

LEGEND OF ABBREVIATIONS
B = Brilacidin, the antibiotic
K = Kevetrin, the oncology drug
P = Prurisol, the psoriasis drug
SAE = Serious Adverse Event
IND = Investigational New Drug


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LSTA News